Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

VOLUNTARY ANNOUNCEMENT

NMPA CONDITIONALLY APPROVES MARKETING FOR THE NEW INDICATION OF TELITACICEPT INJECTION (RC18) FOR THE TREATMENT OF IGA NEPHROPATHY

This announcement is made by RemeGen Co., Ltd. 榮昌生物製藥(煙台)股份有限公司(the "**Company**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has received the Drug Registration Certificate approved and issued by the National Medical Products Administration (the "**NMPA**"). The new indication of Telitacicept Injection (code: RC18, approval number: National Medicine Approval S20260039, certificate number: 2026S01916) for the treatment of IgA nephropathy has been conditionally approved for marketing through the priority review and approval pathway. The dosage form approved for marketing is pre-filled syringe injection.

Pursuant to the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, Telitacicept Injection complies with the relevant requirements for drug registration. This conditional marketing approval is used to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.

Telitacicept is a BLyS/APRIL dual-targeting innovative drug independently developed by the Company, and it is the world's first such molecule. BLyS (B-lymphocyte stimulator) and APRIL (a proliferation-inducing ligand) are key cytokines that promote B cell survival, differentiation and maturation. In patients with IgA nephropathy, overactivation of B cells leads to the production of pathogenic galactose-deficient IgA1 (Gd-IgA1) and immune complex deposition in the glomeruli. By simultaneously inhibiting the binding of BLyS and APRIL to B cell surface receptors, Telitacicept blocks abnormal B cell differentiation and maturation, thereby reducing the production of Gd-IgA1 and alleviating renal injury.

IgA nephropathy is a chronic progressive autoimmune-related glomerular disease and one of the leading causes of end-stage renal disease worldwide. The conditional approval of this new indication is based on the significant efficacy and favorable safety profile demonstrated in the completed Phase II clinical study (18C014) and the Phase III clinical study (18C021) Part A of Telitacicept in the treatment of IgA nephropathy. Data from the Phase II study (18C014) showed that the two Telitacicept treatment groups had significant differences compared with the placebo group in reducing urinary protein, slowing the decline of estimated glomerular filtration rate (eGFR), and reducing immunoglobulin (IgA, IgG and IgM) levels, preliminarily validating the efficacy and safety of Telitacicept in the treatment of IgA nephropathy. The primary efficacy endpoint of Phase III study (18C021) Part A was the change from baseline in urinary protein-to-creatinine ratio (UPCR) at week 39. The primary analysis results showed that at week 39, the Telitacicept 240 mg group achieved a 59% reduction in UPCR from baseline, with a placebo-adjusted reduction rate of 55%. The study met its primary efficacy endpoint in Part A with a favorable safety profile. The detailed study data were published in May 2026 in The New England Journal of Medicine, a top-tier international medical journal.

The approval of this new indication has further enhanced the market competitiveness of Telitacicept. Due to the characteristics of the pharmaceutical industry, the commercialization of the drugs after marketing approval is subject to various factors including policy environment, market demand and competitive landscape, which entail certain uncertainties. The Company will fulfill its information disclosure obligations in a timely manner in accordance with subsequent developments. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, The People's Republic of China
June 8, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* *For identification purpose only*